Briefing
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Observational study of ctDNA to predict ovarian-cancer recurrence by assessing residual disease (estimated n=45). ClinicalTrials.gov API v2 on 13 Nov 2026: status UNKNOWN, start 2022-10-07, primary completion 2024-12-30, last update 2024-02-01. No peer-reviewed primary results paper was identified in this review.
- Design: Not reported · Unknown
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)